Swedish Orphan, Under Pressure At Home, Looks to Commerical Swap With China Company For Growth
This article was originally published in PharmAsia News
Executive Summary
Swedish Orphan Biovitrum AB and partner Dongbao Enterprise Group Co.. have identified intravenous iron for anemia as the first product to be included in their previously announced commercial alliance. The move comes as SOBI ended its deal to distribute Amgen's Mimpara (cinacalcet) in the Nordic territories, the second time it has returned Scandinavian marketing rights to a partner in the past three months
You may also be interested in...
Korea's BL&H To Distribute Swedish Orphan Biovitrum's Orphan Disease Products
SEOUL - South Korean drug importer and distributor BL&H inked a distribution deal with Swedish Orphan Biovitrum for the latter's two orphan disease products Orfadin and Kepivance in Korea
Korea's BL&H To Distribute Swedish Orphan Biovitrum's Orphan Disease Products
SEOUL - South Korean drug importer and distributor BL&H inked a distribution deal with Swedish Orphan Biovitrum for the latter's two orphan disease products Orfadin and Kepivance in Korea
Emerging-Market Specialist Nycomed Acquires Majority Stake In China's Guangdong Techpool Bio-Pharma
Following through on a goal to expand operations in one of the world's fastest growing markets, Nycomed AS confirmed Nov. 1 that it is beefing up its Chinese presence through the acquisition of a majority stake in Guangdong Techpool Bio-Pharma